# What the 2026 Bremelanotide Label Reports About Safety

- Article ID: research-305
- Product: PT-141 (pt-141-449)
- Canonical page: https://heritagebiolabs.com/research-library/articles/305-what-the-2026-bremelanotide-label-reports-about-safety
- Product collection: https://heritagebiolabs.com/research-library/products/pt-141
- Product page: https://heritagebiolabs.com/product/pt-141-449
- Reading focus: Methods & identity (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short chains of amino acids joined by peptide bonds. A peptide that activates a receptor may affect several biological processes, so a clinical study must record unwanted effects alongside intended effects. PT-141 is also known as bremelanotide. The October 2026 US label for the approved product, Vyleesi, records safety findings from its clinical evaluation. Those findings apply to that specific drug product and the settings in which it was studied. [1]

Nausea was the most commonly reported adverse reaction. In the phase 3 controlled trials summarized in the label, 40 percent of participants receiving Vyleesi reported it. Some stopped participating because of nausea. Flushing and headache were also recorded more often than in the placebo group. Looking at both the frequency of symptoms and whether people discontinued provides a clearer account of tolerability than the frequency alone. [1]

The label also describes temporary increases in blood pressure and reductions in heart rate. It lists uncontrolled hypertension and known cardiovascular disease as contraindications. Another warning concerns areas of increased skin pigmentation, which did not always resolve in the clinical record. Different adverse effects have different relevance depending on the person and the outcome being studied. A finding that many events were temporary does not erase a contraindication or establish the safety of an uncharacterized formulation. [1]

Safety evidence is inseparable from the preparation and study population. The approved product has labeling based on reviewed evidence. A different material offered under the same molecule name does not automatically share that evidence. The current label provides a useful source for understanding how benefits and harms were evaluated for the specific prescription product. [1]

## Sources

1. US Food and Drug Administration. Vyleesi (bremelanotide) prescribing information. Drugs@FDA (revised 2026-10). <https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/210557s005lbl.pdf>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 061 - Pinealon and PT-141.docx; article 305; content SHA-256 79c67b971ab345ec8e52805994fb4333857b02923d749da0ccbe8c3f32227bd5.
